stockrowAbCellera Biologics Inc.
ABCL Healthcare Biotechnology
AbCellera Biologics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $75.1 million, up 160.6% from fiscal 2024.
- Revenue
- −76.3%
- EPS
- −50.0%
- Free cash flow
- +152.0%
Quarter to June 2026, against a year earlier
Follow ABCL
Alert me
AbCellera Biologics Inc. (ABCL) Return on invested capital
AbCellera Biologics Inc.'s return on invested capital over the twelve months to 30 June 2026 was −42.5%, down 9.3 percentage points from fiscal 2025 (−33.3%). Over the past ten years it has ranged from −48.5% (fiscal 2024) to 46.0% (fiscal 2021); the current reading is higher than 50% of that period. That is below the Biotechnology industry median of 0.00% and below the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | −33.3% | 15.27 |
| FY2024 | −48.5% | (8.09) |
| FY2023 | −40.4% | (82.48) |
| FY2022 | 42.1% | (3.95) |
| FY2021 | 46.0% | 4.75 |
| FY2020 | 41.3% | 83.14 |
| FY2019 | −41.9% | (41.89) |
| FY2018 | 0.00% | — |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| ARQT Arcutis Biotherapeutics, Inc. compare | 23.5% |
| ACAD ACADIA Pharmaceuticals Inc. compare | 18.6% |
| RLAY Relay Therapeutics, Inc. compare | 0.00% |
| EWTX Edgewise Therapeutics, Inc. compare | 0.00% |
| PBLS Parabilis Medicines, Inc. compare | 0.00% |
| IOVA Iovance Biotherapeutics, Inc. compare | −17.7% |
| ABCL AbCellera Biologics Inc. | −42.5% |
| XENE Xenon Pharmaceuticals Inc. compare | −88.5% |
| TNGX Tango Therapeutics, Inc. compare | −808.4% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)
More on ABCL
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement